Piper Sandler downgraded Repro Med Systems from Overweight to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/25/2024 | $4.00 | Buy | B. Riley Securities |
| 9/7/2023 | $4.00 | Buy | Lake Street |
| 9/7/2023 | $4.50 | Buy | B. Riley Securities |
| 11/10/2022 | $3.00 → $4.00 | Hold → Buy | Canaccord Genuity |
| 11/10/2022 | $3.00 → $3.50 | Neutral → Overweight | Piper Sandler |
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced preliminary unaudited revenues for the second quarter 2023 and provided business, outlook and executive updates. The Company reported total net revenues for the second quarter 2023 of approximately $6.9 million, representing growth of approximately 6% compared to the prior year period. Domestic Core revenues increased approximately 8%, International Core revenues increased approximatel
B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00
B. Riley Securities initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.50
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)
8-K - KORU Medical Systems, Inc. (0000704440) (Filer)
SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)
SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)
SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)
4 - KORU Medical Systems, Inc. (0000704440) (Issuer)
KORU Medical Systems (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced preliminary unaudited results for the fourth quarter and full year ended December 31, 2024. Financial Results (unaudited) Preliminary, unaudited fourth quarter 2024 net revenues expected to be $8.9 million, representing growth of 23% over the prior year period Preliminary, unaudited full year 2024 net revenues expected to be $33.7 million, representing growth of 18% over the prior year Ending cash balance of $9.6 mil
KORU Medical Systems (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will participate in Piper Sandler's 36th Annual Healthcare Conference on December 5, 2024. KORU Medical's management is scheduled to present at Piper Sandler's 36th Annual Healthcare Conference on December 5, 2024, at 11:00 am ET. Interested parties can access the live and archived webcast on the News/Events page of the Investors section of KORU Medical's website at www.korumedical.com. About KORU Medical S
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2024, and raised full year 2024 revenue, gross margin, and year-end cash guidance. Recent Highlights Third quarter 2024 net revenues of $8.2 million, a 17% increase over the prior year period Core business (U.S. and International) growth of 11% and novel therapies growth of 276% over the prior year period Gross profit of $5.2 million, a 19% increase over
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the third quarter ended September 30, 2024, and raised full year 2024 revenue, gross margin, and year-end cash guidance. Recent Highlights Third quarter 2024 net revenues of $8.2 million, a 17% increase over the prior year period Core business (U.S. and International) growth of 11% and novel therapies growth of 276% over the prior year period Gross profit of $5.2 million, a 19% increase over
KORU Medical Systems (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report third quarter 2024 financial results on Wednesday, November 13, 2024. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international call
KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the second quarter ended June 30, 2024 and raised full year 2024 revenue and gross margin guidance. Financial Highlights Second quarter 2024 net revenues of $8.4 million, a 22% increase over the prior year with record-high quarterly revenues Core business (U.S. and International) growth of 20% over the prior year driven by overall SCIg market growth, share gains, and geographic expansion Gross